Thursday, July 10, 2008 Stock Alert Update DigitalPost (OTCBB: DGLP) 5 STRONG REASONS TO BUY!!! DigitalPost Interactive (BB: DGLP) is a stock we have monitored since it went public about two years ago. In just about every case we have mentioned the stock, it has rallied at least 50% following our call. In this case, we are looking for no less than a 100% move over yesterday’s closing price of .091 per share within 30 days. In fact, we believe the stock is so oversold right now, we would not be surprised to see a move of 200 to 300%. The Green Baron Report believes (and we think you'll agree) the 5 reasons listed below clearly demonstrate the timing appears to be absolutely perfect for DGLP's next move up. Our 5 Strong Reasons to Buy: 1) Oversold on light volume - DGLP has drifted lower over the past four weeks on dismal volume in a challenging general market climate devoid of many buyers. There does not appear to be any technical resistance in DGLP until at least .25 per share. Any new fundamental press could blow that number out of the water. 2) Fantastic recent fundamental press releases – Two new partnerships with major names like Westgate Resorts (#3 Timeshare Company in the world) and Kiddie Kandids (top 5 in digital photography and exclusive operator in Baby’s R Us) should begin to contribute dramatically to revenues in Q3 (which just started) and Q4 respectively. The projected numbers from these two contracts are ongoing and staggering. 3) Key fundamental shift in corporate direction – Rather than add clients through word of mouth or advertising, DigitalPost has chosen to grow by private labeling its system to major established businesses. The Green Baron Report believes the announcement with Kiddie Kandids put them over the edge, and will prove to be the turning point in its history. The amazing part is now you can buy DGLP at a 50% discount to when that PR was announced. 4) New year low - Yesterday’s late day general market selloff of over 200 points may have spooked someone into dumping about 50,000 shares at market sending the stock from .14 per share to a new all time low of .091 per share. We think any buy below .15 per share is a gift. 5) The wild card – DigitalPost is supported by an experienced and savvy management team. They have struck partnerships and co-marketing arrangements with huge companies. A new low in its stock price is typically a wakeup call for action, and we believe the Company will deliver. The Green Baron Report is aware that the stock market has not been kind to investors over the past few months, and we are treading cautiously in this environment. However, we will continue to pinpoint specific low priced stock ideas we believe are ripe for huge moves up. We thrive on these types of market opportunities, and this is the kind of market where fortunes are made. Let DGLP help make yours! About DigitalPost Interactive DigitalPost Interactive is a SaaS (Software as a Service) and application provider that delivers B2B and B2C digital media-sharing solutions that are both easy to offer and easy to use. The company's visually-stunning, user-friendly Web 2.0 technology gives consumers a single, engaging place online for permanently storing and sharing a lifetime of digital media and memories, connecting with family and friends, and keeping organized in today's digital world. Completely scaleable and re-brandable, DigitalPost Interactive's technology gives companies in the photo, travel, entertainment, sports, and other vertical markets a fast and efficient way to offer dynamic Web 2.0 products and services. This technology can create exciting new revenue streams for all companies looking to monetize this emerging new internet opportunity. For more information about DigitalPost Interactive or its consumer sites like www.TheFamilyPost.com, please visit www.dglp.com.
Stock Alert Update U.S. Mine Makers, Inc. (PK: USMM) USMM continues to trade lightly at our “Stock Alert” price of .09 bid offered at .10 per share. The Green Baron Report believes it is just a matter of time before USMM becomes widely noticed. CEO Ron Bell and his experienced Board of Directors form what we believe could be the biggest growth story in the stock market for years to come. Precious metal recovery from existing ore concentrates is big business, and U.S. Mine Makers is structured to benefit from the huge rise in gold and PGM’s over the past few years. U.S. Mine Makers will be making appearances on Money TV over the next several months, and the show can be viewed at www.moneytv.net. We suggest members to become fully acquainted with U.S. Mine Makers because we believe this stock could very likely wind up being our best pick ever. About U.S. Mine Makers, Inc. U.S. Mine Makers, Inc. is a mining and exploration company using 'eco-friendly' technology to recover precious metals such as gold and platinum group metals from high grade ore concentrate and rock. Besides its precious metals mining operations, the company also prides itself as an 'eco-friendly' mine restoration company that uses its own modern technology to clean up toxic mine sites. The company motto is, "We Clean the Planet -- One Mine Site at a Time." U.S. Mine Makers, Inc. has executive offices in Palm Desert, California and maintains a web site at: www.usminemakers.com. CONTACT: U.S. Mine Makers, Inc. Ron Bell (800) 220-1822
Focus Stock Update Znomics, Inc. (BB: ZNOM) News Released Yesterday Znomics and Leading Chemist at Oregon Health & Science University Launch Drug Discovery Program for Treatment of Inflammatory Diseases Znomics is a fantastic biotechnology story that came public at a rough period. There have been several times over the past twenty years when a stock like this would have rallied to $10 or $20 per share after going public. However, the market environment right now is more challenging and demanding than ever. Although Znomics remains near our profile price, it has not demonstrated any trading action to speak of. We hope to see ZNOM initiate an upward move soon. Yesterday, Znomics announced yet another new drug discovery program that should get investor’s attention sooner or later. This new program will be headed by a current member of Znomics’ Scientific Advisory Board, Dr. Thomas Scanlan and will focus on the design and development of compounds to treat diseases such as rheumatoid arthritis, asthma and inflammatory bowel syndrome. Company Funds Laboratory of Professor Thomas Scanlan, Ph.D.; Acquires Exclusive Option to License Small Molecule Compounds From the Discovery ProgramPORTLAND, Ore., July 9, 2008 (PRIME NEWSWIRE) -- Znomics, Inc. (OTCBB:ZNOM), a pioneer in the development of the zebrafish as a vertebrate genetic platform to accelerate drug discovery, announced today a collaborative research program with Oregon Health & Science University (OHSU) and Thomas Scanlan, Ph.D., Director of its Chemical Biology Program, to design and develop pre-clinical compounds to treat diseases such as rheumatoid arthritis, asthma and inflammatory bowel syndrome. "This is an important new therapeutic program for Znomics," said Richard Sessions, CEO of Znomics. "Dr. Scanlan has a proven record of designing new compounds that have progressed from the university setting into commercial development and clinical studies. We're extremely pleased to have a research chemist of Tom's caliber collaborating with us." With this collaboration, the company has met its objective this year of establishing three de novo drug discovery programs with the goal of having three pre-clinical lead compounds in different disease areas in 2010. The programs announced in the second quarter of 2008 include a drug discovery program in obesity and a collaborative drug discovery program to develop compounds for the treatment of T-cell diseases, including leukemia, lymphoma and autoimmune disorders. Under the research agreement, Znomics will fund the program and will have the option to exclusively license the rights to the discoveries. Dr. Scanlan, a professor of physiology and pharmacology at OHSU, has conducted leading work in biological research and small molecule discovery in "dissociating glucocorticoid" compounds that retain the desired anti-inflammatory action but without having the serious side effects of steroids. His work has been recognized by the American Chemical Society, which awarded him the prestigious Arthur C. Cope Scholar Award in July 2007. Dr. Scanlan has been a member of Znomics' Scientific Advisory Board since December 2007. "I'm excited about this project and about having Tom more involved with Znomics," said Bruce Beutel, chief scientific officer of Znomics. "The factors involved in glucocorticoid activity represent the kind of complex biology, involving different effects on multiple genes and organs, where our zebrafish whole animal approach can make a significant difference in the drug discovery process." "Having the talented Znomics group in close proximity enables us to efficiently leverage resources for this project," said Dr. Scanlan. "Nothing would please me more than to find a drug that could lead to improved long term treatment for patients suffering from debilitating inflammation-related diseases, which is a large unmet medical need." About Znomics Znomics, Inc. is focused on identifying and developing new pharmaceutical products for treatment of human disorders and diseases. The company's drug discovery platform is based on its catalogued library of mutations in the zebrafish, called the ZeneMark Library. The library, the first in a vertebrate, currently contains more than 11,000 strains of fish representing mutations in approximately half of the known genome. Zebrafish share 80% - 90% of the same genes as humans. The company is leveraging this technology for its internal drug discovery efforts as well as establishing collaborative partnerships with pharmaceutical companies and universities. For more information, visit www.znomics.com Forward-Looking Statements With the exception of historical information contained in this press release, the matters described herein are forward-looking statements that involve risks and uncertainties. Any forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, including statements as to industry trends, future economic performance, anticipated profitability, anticipated revenues or expenses, and products or service line growth, may be significantly and materially impacted by certain risks and uncertainties, including, but not limited to, failure to execute on the strategic plan, failure to meet operating objectives or to execute the operating plan, competition, and other economic factors, risks regarding product development, the timing and results of clinical trials, the regulatory approval process, capital requirements, financial condition, patent protection and dependence on third parties for development and licensing arrangements. Additional risks and uncertainties are described in the Company's public filings with the Securities and Exchange Commission, available online at www.sec.gov. Znomics undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. For more information, visit our website at www.znomics.com For Further Information Contact: Znomics, Inc. Richard Sessions, Chief Executive Officer (503) 827-5271 ext 102
Kerry Rea, Chief Financial Officer (503) 827-5271 ext 101
Pondel/Wilkinson Inc. Investor Relations: Rob Whetstone Eileen Rauchberg (310) 279-5980
|
